Results 11 to 20 of about 5,639 (139)

Pulmonary veno-occlusive disease: illustrative cases and literature review [PDF]

European Respiratory Review
Pulmonary veno-occlusive disease (PVOD), also known as “pulmonary arterial hypertension (PAH) with overt features of venous/capillary involvement”, is a rare cause of PAH characterised by substantial small pulmonary vein and capillary involvement ...
Benoit Lechartier, Athénaïs Boucly, Sabina Solinas, Deepa Gopalan, Peter Dorfmüller, Teodora Radonic, Olivier Sitbon, David Montani   +7 more
doaj   +3 more sources

Anti-synthetase syndrome-associated pulmonary veno-occlusive disease [PDF]

Pulmonary Circulation, 2020
Pulmonary arterial hypertension has been reported with a prevalence of 7.9% in patients with anti-synthetase syndrome; however, anti-synthetase syndrome associated with pulmonary veno-occlusive disease (PVOD) has never before been described in the ...
Dana Kay, Ferdous Kadri, Garrett Fitzpatrick, Hassan Alnuaimat, Raju Reddy, Ali Ataya   +5 more
doaj   +3 more sources

Pulmonary veno-occlusive disease in Sjogren's syndrome: a case report [PDF]

BMC Pulmonary Medicine, 2023
Background Pulmonary arterial hypertension (PAH) associated with connective tissue disease (CTD) belongs to Group 1 pulmonary hypertension. Pulmonary veno-occlusive disease (PVOD), which is characterized by venous system aberrations, has been previously ...
Xiaofang Zeng, Qiong Liu, Anandharajan Rathinasabapathy, Lihuang Zha, Dongliang Liu, Yiyang Tang, Jing Sun, Hui Luo, Zaixin Yu   +8 more
doaj   +3 more sources

Pulmonary arterial hypertension associated with pulmonary arteriovenous malformations and pulmonary veno-occlusive disease: A devastating combination [PDF]

Respiratory Medicine Case Reports, 2021
We describe a case of an adolescent male with the rare combination of pulmonary arterial hypertension (PAH) and pulmonary arteriovenous malformations (PAVM's) without confirmed hereditary hemorrhagic telangiectasia (HHT).
Baukje M. Zaaijer, Nienke Duppen, Brigitte W.M. Willemse, Martijn V. Verhagen, Marcus T.R. Roofthooft, Wim Timens, Rolf M.F. Berger, Johannes M. Douwes   +7 more
doaj   +4 more sources

Outcomes and risk assessment in pulmonary veno-occlusive disease [PDF]

ERJ Open Research
Introduction Pulmonary veno-occlusive disease (PVOD) is a rare and severe subtype of pulmonary arterial hypertension (PAH). Although European Society of Cardiology/European Respiratory Society (ESC/ERS) guidelines advise assessing PAH severity at ...
Athénaïs Boucly, Sabina Solinas, Antoine Beurnier, Xavier Jaïs, Sophia Keddache, Mélanie Eyries, Andrei Seferian, Mitja Jevnikar, Anne Roche, Sophie Bulifon, Arnaud Bourdin, Ari Chaouat, Vincent Cottin, Laurent Bertoletti, Laurent Savale, Marc Humbert, Olivier Sitbon, David Montani   +17 more
doaj   +3 more sources

Mechanisms underlying age-associated exacerbation of pulmonary veno-occlusive disease [PDF]

JCI Insight
Pulmonary veno-occlusive disease (PVOD) is a rare but severe form of pulmonary hypertension characterized by the obstruction of pulmonary arteries and veins, causing increased pulmonary artery pressure and leading to right ventricular (RV) heart failure.
Amit Prabhakar, Meetu Wadhwa, Rahul Kumar, Prajakta Ghatpande, Aneta Gandjeva, Rubin M. Tuder, Brian B. Graham, Giorgio Lagna, Akiko Hata   +8 more
doaj   +3 more sources

Pulmonary veno-occlusive disease: Two children with gradual disease progression

Respiratory Medicine Case Reports, 2017
Pulmonary veno-occlusive disease and pulmonary capillary hemangiomatosis are rare forms of pulmonary vascular disease. We report two cases of affected children who had evidence of pulmonary hypertension 3–5 years before developing radiographic findings ...
Ronald W. Day, Parker W. Clement, Aimee O. Hersh, Susan M. Connors, Kelli L. Sumner, D. Hunter Best, Mouied Alashari   +6 more
doaj   +2 more sources

Gemcitabine-Induced Pulmonary Toxicity: A Case Report of Pulmonary Veno-Occlusive Disease

Clinical Medicine Insights: Oncology, 2015
Introduction Gemcitabine is a chemotherapeutic agent frequently used by for the treatment of several malignancies both in the adjuvant and metastatic setting.
Célia Turco, Marine Jary, Stefano Kim, Mélanie Moltenis, Bruno Degano, Philippe Manzoni, Thierry Nguyen, Bruno Genet, Marie-Blanche Valnet Rabier, Bruno Heyd, Christophe Borg   +10 more
doaj   +3 more sources

Long-term sildenafil therapy for pulmonary veno-occlusive disease in association with melphalan therapy for multiple myeloma: A case report [PDF]

SAGE Open Medical Case Reports
Pulmonary veno-occlusive disease has a significantly worse prognosis than idiopathic pulmonary arterial hypertension. According to a case series from France, the median survival time from diagnosis to death or lung transplantation was only 1 year, and in
Christian Hesse, Gabor Kovacs, Stefan Scheidl, Horst Olschewski   +3 more
doaj   +2 more sources

Pulmonary Veno-Occlusive Disease: A Rare Cause of Pulmonary Hypertension

Journal of Investigative Medicine High Impact Case Reports, 2019
Pulmonary veno-occlusive disease (PVOD) is a rare entity that is usually mistaken with pulmonary arterial hypertension (PAH) but is considered class I′ of PAH. It is important to subclassify PVOD and distinguish it from PAH as treatment with vasodilators
Said Hajouli MD, Muhamad Alhaj Moustafa MD, Jessica S. Wang Memoli MD   +2 more
doaj   +2 more sources